超40年合资历程，中美施贵宝走向重组。2月4日晚，上海医药发布公告，拟通过产权交易所以公开挂牌方式，转让其所持中美上海施贵宝制药有限公司（以下简称“中美施贵宝”）30%的股权，挂牌底价不低于人民币10.23亿元。此前，已有消息称百时美施贵宝将其持有的60%股权出售给高瓴资本，上海医药此次转让股权，也标志着中美施贵宝这一拥有超40年历史的合资企业正式步入洗牌易主阶段。 此次股权转让背后，是中美...
Source Link超40年合资历程，中美施贵宝走向重组。2月4日晚，上海医药发布公告，拟通过产权交易所以公开挂牌方式，转让其所持中美上海施贵宝制药有限公司（以下简称“中美施贵宝”）30%的股权，挂牌底价不低于人民币10.23亿元。此前，已有消息称百时美施贵宝将其持有的60%股权出售给高瓴资本，上海医药此次转让股权，也标志着中美施贵宝这一拥有超40年历史的合资企业正式步入洗牌易主阶段。 此次股权转让背后，是中美...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.